Accord Healthcare launches generic BiCNU

Accord Healthcare has added carmustine to its line of chemotherapy drugs. The drug is formulated as a sterile lyophilized (freeze-dried) powder to be reconstituted for intravenous infusion.

Carmustine is the generic of Avet Pharmaceuticals’ BiCNU and is approved for use in the treatment of certain types of brain tumors and blood cancers.

[Read more: Accord Healthcare launches generic Viibrydr]

Accord is offering carmustine in a 50 mg size, as well as the new, larger 300 mg strength, which was not previously available in the market and overcomes the potential need to use multiple vials of the smaller size, the company said.

"We are proud to be able to provide carmustine lyo. injection in a unique dosage size that is not currently available in the market," said Kevin Congdon, Accord's vice president of institutional sales. "Adding this chemotherapy drug to our portfolio illustrates Accord's commitment in the U.S. market to support healthcare providers in prescribing accessible oncology medications."

[Read more: Accord Healthcare launches generic Alimta]

Carmustine lyo. injection is used alone or with other drugs to treat glioblastoma, astrocytoma, medulloblastoma and other types of malignant brain tumors; relapsed or refractory Hodgkin's lymphoma (the disease has recurred or has not gotten better with other treatment); multiple myeloma, a blood cancer that affects the bone marrow; and relapsed or refractory non-Hodgkin lymphoma (the disease has recurred or has not gotten better with other treatment).